Alarcon N, Jaramillo M, Mansour H, Sun B
Pharmaceutics. 2022; 14(7).
PMID: 35890342
PMC: 9325128.
DOI: 10.3390/pharmaceutics14071448.
Davis L, Tarduno A, Lu Y
Cancers (Basel). 2021; 13(23).
PMID: 34885172
PMC: 8657037.
DOI: 10.3390/cancers13236061.
Wang X, Almazan F, Montoyo-Pujol Y, Martin-Casares A, Martin A, Cabrera T
J Oncol. 2021; 2021:3801143.
PMID: 34630564
PMC: 8497119.
DOI: 10.1155/2021/3801143.
Balhorn R, Balhorn M
Oncotarget. 2020; 11(35):3315-3349.
PMID: 32934776
PMC: 7476732.
DOI: 10.18632/oncotarget.27709.
Mac Keon S, Bentivegna S, Levy E, Marks M, Mantegazza A, Wainstok R
Vaccine. 2019; 37(35):4947-4955.
PMID: 31307876
PMC: 7713901.
DOI: 10.1016/j.vaccine.2019.07.018.
Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen.
Vigneron N, Ferrari V, Van den Eynde B, Cresswell P, Leonhardt R
J Immunol. 2018; 201(7):1875-1888.
PMID: 30135181
PMC: 6457910.
DOI: 10.4049/jimmunol.1701479.
Hitting the Target: How T Cells Detect and Eliminate Tumors.
Zamora A, Crawford J, Thomas P
J Immunol. 2018; 200(2):392-399.
PMID: 29311380
PMC: 6116355.
DOI: 10.4049/jimmunol.1701413.
Tools to define the melanoma-associated immunopeptidome.
Braunlein E, Krackhardt A
Immunology. 2017; 152(4):536-544.
PMID: 28755382
PMC: 5680071.
DOI: 10.1111/imm.12803.
Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes.
Heinrich B, Klein J, Delic M, Goepfert K, Engel V, Geberzahn L
Onco Targets Ther. 2017; 10:2389-2401.
PMID: 28496337
PMC: 5422459.
DOI: 10.2147/OTT.S126320.
Immune targets and neoantigens for cancer immunotherapy and precision medicine.
Wang R, Wang H
Cell Res. 2016; 27(1):11-37.
PMID: 28025978
PMC: 5223235.
DOI: 10.1038/cr.2016.155.
Identification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4.
Lopez M, Ghidouche A, Rochas C, Godelaine D, Carrasco J, Colau D
Cancer Immunol Immunother. 2016; 65(10):1177-88.
PMID: 27514672
PMC: 11029526.
DOI: 10.1007/s00262-016-1877-7.
Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity.
Omokoko T, Luxemburger U, Bardissi S, Simon P, Utsch M, Breitkreuz A
J Immunol Res. 2016; 2016:9540975.
PMID: 27057556
PMC: 4736447.
DOI: 10.1155/2016/9540975.
The role of neoantigens in response to immune checkpoint blockade.
Riaz N, Morris L, Havel J, Makarov V, Desrichard A, Chan T
Int Immunol. 2016; 28(8):411-9.
PMID: 27048318
PMC: 4986233.
DOI: 10.1093/intimm/dxw019.
Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.
Martin S, Coukos G, Holt R, Nelson B
Ann Oncol. 2015; 26(12):2367-74.
PMID: 26371284
PMC: 4658541.
DOI: 10.1093/annonc/mdv382.
Human Tumor Antigens and Cancer Immunotherapy.
Vigneron N
Biomed Res Int. 2015; 2015:948501.
PMID: 26161423
PMC: 4487697.
DOI: 10.1155/2015/948501.
Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex.
Vigneron N, Van den Eynde B
Biomolecules. 2014; 4(4):994-1025.
PMID: 25412285
PMC: 4279167.
DOI: 10.3390/biom4040994.
Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma.
Yuan J, Ku G, Adamow M, Mu Z, Tandon S, Hannaman D
J Immunother Cancer. 2014; 1:20.
PMID: 24829756
PMC: 4019903.
DOI: 10.1186/2051-1426-1-20.
Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.
Moehler M, Goepfert K, Heinrich B, Breitbach C, Delic M, Galle P
Front Oncol. 2014; 4:92.
PMID: 24822170
PMC: 4013456.
DOI: 10.3389/fonc.2014.00092.
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.
Coulie P, Van den Eynde B, van der Bruggen P, Boon T
Nat Rev Cancer. 2014; 14(2):135-46.
PMID: 24457417
DOI: 10.1038/nrc3670.
Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.
Wang H, Wang R
Adv Immunol. 2012; 114:151-76.
PMID: 22449781
PMC: 3760162.
DOI: 10.1016/B978-0-12-396548-6.00006-8.